{
    "clinical_study": {
        "@rank": "146266", 
        "arm_group": {
            "arm_group_label": "FANG", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase II study of FANG\u2122 autologous tumor cell vaccine integrated with\n      carboplatinum. All patients will have had FANG\u2122 prepared and stored from ovarian tumor cells\n      obtained at the time of primary surgical debulking. Patients meeting eligibility criteria\n      will receive either carboplatinum alone (AUC 6/30 minute infusion) (or carboplatinum (AUC\n      5/30 minute infusion) and taxol (175 mg/m2/3 hour infusion)one day prior to FANG\u2122 1.0 x 10e7\n      cells/intradermal injection, once every 3 weeks."
        }, 
        "brief_title": "Salvage Ovarian FANG Vaccine + Carboplatinum", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stage III Ovarian Cancer", 
            "Stage IV Ovarian Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed papillary serous or endometrioid ovarian cancer.\n\n          2. Previous randomization to Gradalis, Inc. protocol CL-PTL 105; observation arm (Group\n             B) or or patients with vaccine prepared for CL-PTL 105 but did not otherwise qualify.\n\n          3. Recurrent cisplatinum-sensitive disease (defined as the appearance of any measurable\n             or evaluable lesion or as asymptomatic CA-125 levels greater than 100 u/mL at two\n             consecutive measurements after a 6 month period after platinum treatment.\n\n          4. Successful manufacturing of 4 vials of FANG\u2122 vaccine.\n\n          5. Recovered from all clinically relevant toxicities related to prior therapies.\n\n          6. ECOG PS 0-2 prior to FANG\u2122 vaccine administration.\n\n          7. Normal organ and marrow function as defined below:\n\n               1. Absolute granulocyte count \u2265 1,500/mm3\n\n               2. Absolute lymphocyte count \u2265 200/mm3\n\n               3. Platelets \u2265 100,000/mm3\n\n               4. Total bilirubin \u2264 1.5 x ULN\n\n               5. AST(SGOT)/ALT(SGPT)/alkaline phosphatase \u2264 2.5 x ULN\n\n               6. Creatinine < 1.5 mg/dL\n\n          8. Patients must be off all \"statin\" drugs for \u2265 2 weeks prior to initiation of therapy.\n\n          9. Ability to understand and the willingness to sign a written informed protocol\n             specific consent.\n\n        Exclusion Criteria:\n\n          1. Surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy, or\n             immunotherapy within 4 weeks prior to vaccination.  Chemotherapy within 3 weeks prior\n             to vaccination.  Steroid therapy within 1 week prior to vaccination.\n\n          2. Patient must not have received any other investigational agents within 4 weeks prior\n             to study entry.\n\n          3. Patients who require parenteral hydration of nutrition and have evidence of partial\n             bowel obstruction or perforation.\n\n          4. Patients with history of brain metastases.\n\n          5. Patients with compromised pulmonary disease.\n\n          6. Short term (<30 days) concurrent systemic steroids \u2264 0.25 mg/kg prednisone per day\n             (maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other\n             steroid regimens and/or immunosuppressives are excluded.\n\n          7. Prior splenectomy.\n\n          8. Prior malignancy (excluding nonmelanoma carcinomas of the skin and carcinoma in situ\n             cervix) unless in remission for \u2265 2 years.\n\n          9. Kaposi's Sarcoma.\n\n         10. Patients with peripheral neuropathy \u22652 (paclitaxel).\n\n         11. Uncontrolled infection or psychiatric illness/social situations that would limit\n             compliance with study requirements.\n\n         12. Patients with known HIV.\n\n         13. Patients with chronic Hepatitis B and C infection.\n\n         14. Patients with uncontrolled autoimmune diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867086", 
            "org_study_id": "CL-PTL 110"
        }, 
        "intervention": [
            {
                "arm_group_label": "FANG", 
                "description": "Patients meeting eligibility criteria will receive FANG\u2122 1.0 x 10e7 cells/intradermal injection once every 3 weeks.", 
                "intervention_name": "Vaccine: FANG\u2122 Vaccine", 
                "intervention_type": "Biological", 
                "other_name": "bi-shRNA furin and GMCSF Augmented Autologous Tumor Cell Vaccine"
            }, 
            {
                "arm_group_label": "FANG", 
                "description": "Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion)and taxol (175 mg/m2 3 hour infusion one day prior to FANG\u2122 1.0 x 10e7 cells/ intradermal injection, once every three weeks.", 
                "intervention_name": "Carboplatinum", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FANG", 
                "description": "Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion)and taxol (175 mg/m2 3 hour infusion one day prior to FANG\u2122 1.0 x 10e7 cells/ intradermal injection, once every three weeks.", 
                "intervention_name": "Carboplatinum and Taxol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FANG", 
                "intervention_name": "FANG", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "ovarian cancer", 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "contact": {
                "email": "referral@marycrowley.org", 
                "last_name": "Referral Office", 
                "phone": "972-566-3000"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75230"
                }, 
                "name": "Mary Crowley Cancer Research Centers"
            }, 
            "investigator": {
                "last_name": "Minal Barve, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG\u2122) Integrated With Chemotherapy for Patients With Recurrent Cisplatinum Sensitive Ovarian Cancer Participating in Study CL-PTL 105", 
        "overall_official": {
            "affiliation": "Principal Investigator", 
            "last_name": "Minal Barve, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the response rate and time to progression (TTP) following chemotherapy integrated with FANGTM vaccine in patients with ovarian cancer who recurred following standard of care post treatment observation in study CL-PTL 105 as well as in those for whom vaccine was prepared but did not otherwise qualify.", 
            "measure": "Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed up to 24 months"
        }, 
        "reference": {
            "PMID": "22186789", 
            "citation": "Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of \"bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell\" vaccine (FANG) in advanced cancer. Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867086"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To determine the response rate and time to progression (TTP) following chemotherapy integrated with FANGTM vaccine in patients with ovarian cancer who recurred following standard of care post treatment observation in study CL-PTL 105 as well as in those for whom vaccine was prepared but did not otherwise qualify.", 
            "measure": "Time to Progression", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed for 24 months"
        }, 
        "source": "Gradalis, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gradalis, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}